Literature DB >> 23564768

Characterization and evaluation of pre-clinical suitability of a syngeneic orthotopic mouse ovarian cancer model.

Sungpil Cho1, Yongen Sun, Andrew P Soisson, Mark K Dodson, C Matthew Peterson, Elke A Jarboe, Anne M Kennedy, Margit M Janát-Amsbury.   

Abstract

BACKGROUND/AIM: To develop and characterize the pre-clinical suitability of a syngeneic mouse epithelial ovarian cancer model in immunocompetent hosts.
MATERIALS AND METHODS: ID8 mouse ovarian surface epithelium cells were implanted into the left ovarian bursa of C57BL/6 mice. Using conventional as well as ultrasound-based techniques and histopathological analysis, the tumor weights, volumes, metastases, ascites and vascularity were observed over a period of 16 weeks.
RESULTS: Ovarian weights and volume increased 12- and 7-fold, respectively. Ultrasound measurements of ovarian ID8 tumors correlated with the actual size obtained following surgical excision. Ascites and metastasis were first observed at 12 weeks post-orthotopic implantation. Histopathological analysis indicated similarities between orthotopically-generated ovarian tumors and human ovarian tumors. However, there was less evidence of angiogenesis in this animal model.
CONCLUSION: The development of this mouse model closely replicates characteristics seen in human ovarian cancer with feasibility of using ultrasound to assess tumor formation, progression and vascularization.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23564768

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  Enhanced anti-tumor efficacy and safety with metronomic intraperitoneal chemotherapy for metastatic ovarian cancer using biodegradable nanotextile implants.

Authors:  Smrithi Padmakumar; Neha N Parayath; Shantikumar V Nair; Deepthy Menon; Mansoor M Amiji
Journal:  J Control Release       Date:  2019-05-17       Impact factor: 9.776

2.  Improved anti-tumor efficacy of paclitaxel in combination with MicroRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer.

Authors:  Neha N Parayath; Srujan Kumar Gandham; Fraser Leslie; Mansoor M Amiji
Journal:  Cancer Lett       Date:  2019-07-06       Impact factor: 8.679

3.  An immunocompetent, orthotopic mouse model of epithelial ovarian cancer utilizing tissue engineered tumor cell sheets.

Authors:  Ayumi Arauchi; Chieh-Hsiang Yang; Sungpil Cho; Elke A Jarboe; C Matthew Peterson; You Han Bae; Teruo Okano; Margit M Janát-Amsbury
Journal:  Tissue Eng Part C Methods       Date:  2015-01       Impact factor: 3.056

4.  Design and Characterization of Bioengineered Cancer-Like Stem Cells.

Authors:  Sungpil Cho; Hongsuk Park; Elke A Jarboe; C Matthew Peterson; You Han Bae; Margit M Janát-Amsbury
Journal:  PLoS One       Date:  2015-10-21       Impact factor: 3.240

5.  The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway.

Authors:  Juri Ogishima; Ayumi Taguchi; Akira Kawata; Kei Kawana; Mitsuyo Yoshida; Yuki Yoshimatsu; Masakazu Sato; Hiroe Nakamura; Yoshiko Kawata; Akira Nishijima; Asaha Fujimoto; Kensuke Tomio; Katsuyuki Adachi; Takeshi Nagamatsu; Katsutoshi Oda; Tohru Kiyono; Yutaka Osuga; Tomoyuki Fujii
Journal:  BMC Cancer       Date:  2018-12-03       Impact factor: 4.430

6.  Notch3 signaling promotes tumor cell adhesion and progression in a murine epithelial ovarian cancer model.

Authors:  Jessica C Price; Elham Azizi; L A Naiche; Jenny G Parvani; Priyanka Shukla; Seoyeon Kim; Jill K Slack-Davis; Dana Pe'er; Jan K Kitajewski
Journal:  PLoS One       Date:  2020-06-11       Impact factor: 3.240

7.  Assessment of the immune landscapes of advanced ovarian cancer in an optimized in vivo model.

Authors:  Simone Pisano; Stefania Lenna; Gareth D Healey; Fereshteh Izardi; Lucille Meeks; Yajaira S Jimenez; Oscar S Velazquez; Deyarina Gonzalez; Robert Steven Conlan; Bruna Corradetti
Journal:  Clin Transl Med       Date:  2021-10

8.  Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer.

Authors:  Shonagh Russell; Felicia Lim; Pamela N Peters; Suzanne E Wardell; Regina Whitaker; Ching-Yi Chang; Rebecca A Previs; Donald P McDonnell
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

Review 9.  Recent technological advances in using mouse models to study ovarian cancer.

Authors:  Carrie Danielle House; Lidia Hernandez; Christina Messineo Annunziata
Journal:  Front Oncol       Date:  2014-02-13       Impact factor: 6.244

10.  Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.

Authors:  Spencer D Martin; Scott D Brown; Darin A Wick; Julie S Nielsen; David R Kroeger; Kwame Twumasi-Boateng; Robert A Holt; Brad H Nelson
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.